Baldness, benign prostate hyperplasia, prostate cancer and androgen levels

Author： Faydaci Gökhan   Bilal Eryildirim   Necmettin Penpegül   Fatih Tarhan   Asuman Orçun   Uğur KuyumcuoĞlu  

Publisher： Informa Healthcare

ISSN： 1473-0790

Source： The Aging Male, Vol.11, Iss.4, 2008-03, pp. : 189-192

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Benign prostate hyperplasia in the older male

By Sprenkle Preston C   Lowe Franklin C  

Aging Health, Vol. 3, Iss. 2, 2007-04 ,pp. : 177-189

Future Medicine

Access to resources Recommend Favorite

Circadian rhythm of hot flashes and activity levels among prostate cancer patients on androgen deprivation therapy

By Hanisch Laura J.   Gehrman Philip R.  

The Aging Male, Vol. 14, Iss. 4, 2011-12 ,pp. : 243-248

Informa Healthcare

Access to resources Recommend Favorite

The role of alfuzosin in the treatment of benign prostate hyperplasia and acute urinary retention

By Leung Steve KW   McNeill S Alan  

Aging Health, Vol. 2, Iss. 3, 2006-06 ,pp. : 363-369

Future Medicine

Access to resources Recommend Favorite

Androgen treatment and prostate safety

By  

The Aging Male, Vol. 7, Iss. 1, 2004-01 ,pp. : 50-50

Informa Healthcare

Access to resources Recommend Favorite

Does primary androgen-deprivation therapy improve survival for localized prostate cancer?

By Loeb Stacy   Schaeffer Edward M  

Aging Health, Vol. 4, Iss. 5, 2008-10 ,pp. : 451-453

Future Medicine

Access to resources Recommend Favorite